BCL2L1 and plasma cell myeloma: In multiple myeloma, BRD4 and Mediator are enriched at super-enhancers associated with oncogenes including MYC, BCL-xL and IRF4. Treatment of multiple myeloma cells with the BRD4 inhibitor JQ1 results in BRD4 disassociation from super-enhancers, and reduction in MYC, BCL-xL and IRF4 gene expression and multiple myeloma cell proliferation [6].